{
    "startDate": "2021-01-01",
    "endDate": "2021-12-31",
    "year": "2021",
    "quarter": "FY",
    "symbol": "CLBS",
    "data": {
        "bs": [
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 545988000
            },
            {
                "label": "Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2021 and December 31, 2020, respectively",
                "concept": "PreferredStockValue",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Total assets",
                "concept": "Assets",
                "unit": "usd",
                "value": 97008000
            },
            {
                "label": "Accrued liabilities",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 2589000
            },
            {
                "label": "Other long-term liabilities",
                "concept": "OtherLiabilitiesNoncurrent",
                "unit": "usd",
                "value": 485000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -453016000
            },
            {
                "label": "Total current liabilities",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 4523000
            },
            {
                "label": "Accumulated other comprehensive loss",
                "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -70000
            },
            {
                "label": "Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,800,792 and 19,389,413 shares, at December 31, 2021 and December 31, 2020, respectively; and outstanding, 59,789,712 and 19,378,333 shares, at December 31, 2021 and December 31, 2020, respectively",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 60000
            },
            {
                "label": "Non-controlling interests",
                "concept": "MinorityInterest",
                "unit": "usd",
                "value": -254000
            },
            {
                "label": "Total equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 92000000
            },
            {
                "label": "Total equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 92000000
            },
            {
                "label": "Property and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 62000
            },
            {
                "label": "Property and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 62000
            },
            {
                "label": "Other assets",
                "concept": "OtherAssetsNoncurrent",
                "unit": "usd",
                "value": 764000
            },
            {
                "label": "Total current assets",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 96182000
            },
            {
                "label": "Marketable securities",
                "concept": "MarketableSecurities",
                "unit": "usd",
                "value": 70323000
            },
            {
                "label": "Commitments and Contingencies",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Total liabilities",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 5008000
            },
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 24647000
            },
            {
                "label": "Prepaid and other current assets",
                "concept": "PrepaidExpenseAndOtherAssetsCurrent",
                "unit": "usd",
                "value": 1212000
            },
            {
                "label": "Treasury stock, at cost; 11,080 shares at December 31, 2021 and December 31, 2020 respectively",
                "concept": "TreasuryStockValue",
                "unit": "usd",
                "value": 708000
            },
            {
                "label": "Total Caladrius Biosciences, Inc. stockholders' equity",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 92254000
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 1934000
            },
            {
                "label": "Total liabilities, non-controlling interests and equity",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 97008000
            }
        ],
        "cf": [
            {
                "label": "Net cash used in operating activities",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -22245000
            },
            {
                "label": "Net cash used in investing activities",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": -54896000
            },
            {
                "label": "Other assets",
                "concept": "IncreaseDecreaseInOtherOperatingAssets",
                "unit": "usd",
                "value": 150000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Proceeds from exercise of options",
                "concept": "ProceedsFromStockOptionsExercised",
                "unit": "usd",
                "value": 24000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationAndAmortization",
                "unit": "usd",
                "value": 55000
            },
            {
                "label": "Taxes",
                "concept": "IncomeTaxesPaid",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Purchases of property and equipment",
                "concept": "PaymentsToAcquirePropertyPlantAndEquipment",
                "unit": "usd",
                "value": 60000
            },
            {
                "label": "Equity-based compensation expense",
                "concept": "IssuanceOfStockAndWarrantsForServicesOrClaims",
                "unit": "usd",
                "value": 2005000
            },
            {
                "label": "Sales of marketable securities",
                "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
                "unit": "usd",
                "value": 124939000
            },
            {
                "label": "Accounts payable, accrued liabilities and other liabilities",
                "concept": "clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities",
                "unit": "usd",
                "value": 1250000
            },
            {
                "label": "Interest",
                "concept": "InterestPaidNet",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Net cash provided by financing activities",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 85276000
            },
            {
                "label": "Amortization/accretion on marketable securities",
                "concept": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
                "unit": "usd",
                "value": -2514000
            },
            {
                "label": "Tax withholding payments on net share settlement equity awards",
                "concept": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
                "unit": "usd",
                "value": 248000
            },
            {
                "label": "Net proceeds from issuance of capital stock",
                "concept": "ProceedsFromIssuanceOfCommonStock",
                "unit": "usd",
                "value": 85500000
            },
            {
                "label": "Purchase of marketable securities",
                "concept": "PaymentsToAcquireMarketableSecurities",
                "unit": "usd",
                "value": 179775000
            },
            {
                "label": "Net increase in cash and cash equivalents",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                "unit": "usd",
                "value": 8135000
            },
            {
                "label": "Prepaid and other current assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": 453000
            }
        ],
        "ic": [
            {
                "label": "Net loss attributable to Caladrius Biosciences, Inc. common shareholders",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Diluted shares",
                "concept": "WeightedAverageNumberOfDilutedSharesOutstanding",
                "unit": "shares",
                "value": "N/A"
            },
            {
                "label": "Investment income, net",
                "concept": "InvestmentIncomeNet",
                "unit": "usd",
                "value": 151000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Caladrius Biosciences, Inc. common shareholders - diluted (in dollars per share)",
                "concept": "EarningsPerShareDiluted",
                "unit": "usd/shares",
                "value": -0.5
            },
            {
                "label": "Operating expenses",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 29050000
            },
            {
                "label": "Total other income",
                "concept": "NonoperatingIncomeExpense",
                "unit": "usd",
                "value": 76000
            },
            {
                "label": "Benefit from income taxes",
                "concept": "IncomeTaxExpenseBenefit",
                "unit": "usd",
                "value": -1508000
            },
            {
                "label": "Benefit from income taxes",
                "concept": "IncomeTaxExpenseBenefit",
                "unit": "usd",
                "value": -1508000
            },
            {
                "label": "Benefit from income taxes",
                "concept": "IncomeTaxExpenseBenefit",
                "unit": "usd",
                "value": -1508000
            },
            {
                "label": "Caladrius Biosciences, Inc. common shareholders - basic (in dollars per share)",
                "concept": "EarningsPerShareBasic",
                "unit": "usd/shares",
                "value": ""
            },
            {
                "label": "Net loss before benefit from income taxes and noncontrolling interests",
                "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
                "unit": "usd",
                "value": -28974000
            },
            {
                "label": "Net loss before benefit from income taxes and noncontrolling interests",
                "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
                "unit": "usd",
                "value": -28974000
            },
            {
                "label": "Less - net income attributable to noncontrolling interests",
                "concept": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 17680000
            },
            {
                "label": "Basic shares",
                "concept": "WeightedAverageNumberOfSharesOutstandingBasic",
                "unit": "shares",
                "value": 55313000
            },
            {
                "label": "Operating loss",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -29050000
            },
            {
                "label": "General and administrative",
                "concept": "SellingGeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 11370000
            },
            {
                "label": "Other expense, net",
                "concept": "OtherNonoperatingIncomeExpense",
                "unit": "usd",
                "value": -75000
            },
            {
                "label": "Total other comprehensive loss",
                "concept": "OtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -57000
            },
            {
                "label": "Available for sale securities - net unrealized loss",
                "concept": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
                "unit": "usd",
                "value": -57000
            },
            {
                "label": "Comprehensive loss",
                "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -27523000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -27466000
            },
            {
                "label": "Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -27523000
            },
            {
                "label": "Comprehensive income attributable to noncontrolling interests",
                "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": "N/A"
            }
        ]
    }
}